Current molecular imaging of spinal tumors in clinical practice

Molecular Medicine

Volumn 17, Issue 3-4, 2011, Pages 308-316

  Sandu, Nora ^a,b   Pöpperl, Gabriele ^c   Toubert, Marie Elisabeth ^d   Spiriev, Toma ^a,e   Arasho, Belachew ^a,f   Orabi, Mikael ^a   Schaller, Bernhard ^a,f  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Stuttgart General Hospital   (Germany)

^d University of Paris   (France)

^e Tokuda Hospital   (Bulgaria)

^f ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FRAGILITY FRACTURE; GLIOMA; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; LYMPHOMA; MENINGIOMA; METASTASIS POTENTIAL; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MYELOMA; NEURILEMOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; SPINAL CORD TUMOR; SPINE METASTASIS; SPINE TUMOR; SURVIVAL RATE; TISSUE DIFFERENTIATION; TREATMENT INDICATION; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

DISEASE PROGRESSION; HUMANS; MOLECULAR IMAGING; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPINAL CORD NEOPLASMS; SPINAL NEOPLASMS;

EID: 79952855320     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00218     Document Type: Article

References (107)

1. Beaumont A, Whittle IR. (2000) The pathogenesis of tumor associated epilepsy. Acta Neurochir. 142:1-15.
2. Schaller B. (2003) Neuroprotection in brain tumors. Good sense or nonsense from the pathophysiological viewpoint [in German]? Nervenarzt. 74:1134-6.
3. Schaller B. (2005) Influences of brain tumorassociated pH changes and hypoxia on epileptogenesis. Acta. Neurol. Scand. 111:75-83.
4. Schaller BJ, Buchfelder M. (2006) Neuroprotection in primary brain tumors: sense or nonsense? Expert Rev. Neurother. 6:723-30.
5. Sandu N, Schaller B. (2010) Stem cell transplantation in brain tumors: a new field for molecular imaging? Mol. Med. 16:433-7.
6. Sandu N, Schaller B. (2011) Molecular imaging of stem cell therapy: also a solution for brain tumors? Arch. Med. Sci. Forthcoming.
7. Schaller B. (2005) Spinal meningioma: relationship between histological subtypes and surgical outcome? J. Neurooncol. 75:157-61.
8. Schaller B, et al. (2006) Intradural, extramedullary spinal sarcoidosis: report of a rare case and review of the literature. Spine J. 6:204-10.
9. Jacobs AH, et al. (2003) PET-based molecular imaging in neuroscience. Eur. J. Nucl. Med. Mol. Imaging. 30:1051-65.
10. Schaller B. (2005) Positron emission tomography in neuroscience. An integrative part of clinical diagnostic methods and experimental research. [Article in German] Radiologe. 45:186, 188-96.
11. Weissleder R, Mahmood U. (2001) Molecular imaging. Radiology. 219:316-33.
12. Gambhir SS, et al. (2001) A tabulated summary of the PET literature. J. Nucl. Med. 42(suppl):1S-93S.
13. Schaller B. (2004) Usefulness of positron emission tomography in diagnosis and treatment followup of brain tumors. Neurobiol. Dis. 15:437-48.
14. Schaller B. (2008) Strategies for molecular imaging dementia and neurodegenerative diseases. Neuropsych. Dis. Treat 4:585-612.
15. Schaller BJ, Cornelius JF, Sandu N, Buchfelder M. (2008) Molecular imaging of brain tumors: personal experience and review of the literature. Curr. Mol. Med. 8:711-26.
16. Ishikawa M, et al. (1993) Glucose consumption in recurrent gliomas. Neurosurgery. 33:28-33.
17. Patronas NJ, et al. (1985) Prediction of survival in glioma patients by means of positron emission tomography. J. Neurosurg. 62:816-22.
18. Alavi JB, et al. (1988) Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer. 62:l074-8.
19. Hoffman JM, et al. (1993) The prognostic and diagnostic usefulness of FOG-PET in primary brain tumor management. J. Nucl. Med. 34:37P.
20. Mineura K, et al. (1994) Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer. 73:2386-94.
21. Rosenfeld SS, et al. (1992) Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxy glucose positron emission tomography. J. Nucl. Med. 33:532-53.
22. Kuwabara Y, et al. (1988) High 8F-FDG-uptake in primary cerebral lymphoma: a PET study. J. Comput. Assist. Tomogr. 12:47-8.
23. Holthoff VA, et al. (1993) In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer. 72:1394-403.
24. Griffeth LK, et al. (1993) Brain metastases from noncentral nervous system tumors: evaluation with PET. Radiology. l86:37-44.
25. Di Chiro G, et al. (1983) Metabolic imaging of the brain stem and spinal cord: studies with positron emission tomography using 8F-2-deoxyglucosine normal and pathological cases. J. Comput. Assist. Tomogr. 7:937-45.
26. Herholz K, Coope D, Jackson A. (2007) Metabolic and molecular imaging in neuro-oncology. Lancet Neurol. 6:711-24.
27. Pauleit D, et al. (2009) Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl. Med. Biol. 36:779-87.
28. Lau EW, et al. (2010) Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J. Clin. Neurosci. 17:43-9.
29. Pichler R, et al. (2010) Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur. J. Nucl. Med. Mol. Imaging. 37:1521-8.
30. Muhr C. (2006) Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology. 83:205-10.
31. Milker-Zabel S, et al. (2006) Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and (68Ga)-DOTATOCPET. Int. J. Radiat. Oncol. Biol. Phys. 65:222-7.
32. Levivier M, Becerra A, De Witte O, Brotchi J, Goldman S. (1996) Radiation necrosis or recurrence. J. Neurosurg. 84:148-9.
33. Schaller BJ, Modo M, Buchfelder M. (2007) Molecular imaging of brain tumors: a bridge between clinical and molecular medicine? Mol. Imaging Biol. 9:60-71.
34. Schaller B, Cornelius JF, Sandu N. (2008) Molecular medicine successes in neuroscience. Mol. Med. 14:361-4.
35. Buonocore E. (1992) Comparison of PET with conventional imaging techniques. In: Clinical Positron Emission Tomography. Hubner KF, Collmann J, Buonocore E, Kabalka G (eds.) Mosby Year Book, St. Louis, MO, pp. 17-22.
36. Del Sole A, et al. (2001) Anatomical and biochemical investigation of primary brain tumours. Eur. J. Nucl. Med. 28:1851-72.
37. Jasanoff A. (2005) Functional MRI using molecular imaging agents. Trends Neurosci. 28:120-6.
38. Wong TZ, van der Westhuizen GJ, Coleman RE. (2002) Positron emission tomography imaging of brain tumors. Neuroimaging Clin. N. Am. 12:615-26.
39. Hoffman El, Huang SC, Phelps ME. (1979) Quantitation in positron emission CT: I. Effect of object size. J. Comput. Assist. Tomogr. 3:299-308.
40. Kessler RM, Ellis JR, Eden M. (1984) Analysis of emission tomographic scan data: limitations imposed by resolution and background. J. Comput. Assist. Tomogr. 8:514-22.
41. Lütolf M. (2001) Modern imaging for detection and localization of distant metastases [in German]. Ther. Umsch. 58:701-8.
42. Wise JJ, Fischgrund JS, Herkowitz HN, Montgomery D, Kurz LT. (1999) Complication, survival rates, and risk factors of surgery for metastatic disease of the spine. Spine. 24:1943-51.
43. Guise TA. (2006) Bone loss and fracture risk associated with cancer therapy. Oncologist. 11:1121-31.
44. Mazziotta JC, Phelps ME, Plummer D, Kuhl DE. (1981) Quantitation in positron emission tomography: 5. Physical-anatomical effects. J. Comput. Assist. Tomogr. 5:734-43.
45. Wilmshurst JM, et al. (2000) Positron emission tomography in imaging spinal cord tumors. J. Child Neurol. 15:465-72.
46. Shimizu T, et al. (2004) Primary spinal oligoastrocytoma: a case report. Surg. Neurol. 61:77-81.
47. Poggi MM, et al. (2001) Intramedullary spinal cord metastasis from renal cell carcinoma detection by positron emission tomography. Clin. Nucl. Med. 26:837-9.
48. Sasajima T, et al. (1996) Spinal cord ependymoma: a positron emission tomographic study with (11C-methyl)-L-methionine. Neuroradiology. 38:53-5.
49. Higano S, et al. (1990) PET evaluation of spinal cord tumor using 11C-methionine. J. Comput. Assist. Tomogr. 14:297-9.
50. Zhang H, et al. (2004) Carbon-11-methionine positron emission tomography imaging of chordoma. Skeletal Radiol. 33:524-30.
51. Fogelman I, Cook G, Israel O, Van der W.H. (2005) Positron emission tomography and bone metastases. Semin. Nucl. Med. 35:135-42.
52. Peterson JJ, Kransdorf MJ, O'Connor MI. (2003) Diagnosis of occult bone metastases: positron emission tomography. Clin. Orthop. Relat. Res. 415(Suppl):S120-8.
53. McCarthy M, et al. (2011) 18F-fluoromethylcholine (FCH) PET imaging in patients with castrationresistant prostate cancer: prospective comparison with standard imaging. Eur. J. Nucl. Med. Mol. Imaging. 38:14-22.
54. Fletcher JW, et al. (2008) Recommendations on the use of 18FFDG-PET in oncology. J. Nucl. Med. 49:480-508.
55. Ghanem NA, et al. (2007) MRI and 18F FDG- PET in the assessment of bone marrow infiltration of the spine in cancer patients. Eur. Spine J. 16:1907-12.
56. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. (1998) Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J. Clin. Oncol. 16:3375-9.
57. Du Y, Cullum I, Illidge TM, Ell PJ. (2007) Fusion of metabolic function and morphology: sequential 18Ffluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J. Clin. Oncol. 25:3440-7.
58. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. (2004) Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 31(Suppl 1):S125-S134.
59. Nakai T, et al. (2005) Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 32:1253-8.
60. Cook GJ, Fogelman I. (2000) The role of positron emission tomography in the management of bone metastases. Cancer. 88:2927-33.
61. Beheshti M, et al. (2009) The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol. Imaging Biol. 11:446-54.
62. Even-Sapir E, et al. (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, singleand multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. JNM. 47:287-97.
63. Pauleit D, et al. (2005) PET with O-(2-18FFluoroethyl)- L-Tyrosine in peripheral tumors: first clinical results. JNM. 46:411-6.
64. Plotkin M, et al. (2010) Comparison of F-18 FETPET with F-18 FDG-PET for biopsy planning of non- contrast-enhancing gliomas. Eur. Radiol. 20:2496-502.
65. Nuutinen J, et al. (1998) Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur. J. Nucl. Med. 25:729-35.
66. Beaulieu S, et al. (2004) Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR. 182:971-4.
67. Borbely K, Fulham MJ, Brooks RA, Di Chiro G. (1992) PET Fluorodeoxyglucose of cranial and spinal neuromas. J. Nuc. Med. 33:1931-4.
68. Sakamoto H, et al. (2000) Positron emission tomography imaging of acoustic neuromas. Acta Otolaryngol. Suppl. 542:18-21.
69. Liu RS, et al. (2010) 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J. Nucl. Med. 51:883-91.
70. Giovacchini G, et al. (2009) C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin. Nucl. Med. 34:7-10.
71. Ghodsian M, Obrzut SL, Hyde CC, Watts WJ, Schiepers C. (2005) Evaluation of metastatic meningioma with 2-deoxy-2-18Ffluoro-D-glucose PET/CT. Clin. Nucl. Med. 30:717-20.
72. Iuchi T, et al. (1999) Glucose and methionine uptake and proliferative activity in meningiomas. Neurol. Res. 21:640-4.
73. Khan MU, et al. (2009) Clinical indications for Gallium-68 positron emission tomography imaging. Eur. J. Surg. Oncol. 35:561-7.
74. Wu PS, Yao WJ. (2010) F-18 FDG PET in spinal cord pilocytic astrocytoma. Clin. Nucl. Med. 35:649-50.
75. Won KS, Kim JS, Ra YS, Sohn CH, Zeon SK. (2006) FDG PET of primary spinal glioblastoma initially mimicking a transverse myelitis on MRI. Clin. Nucl. Med. 31:556-7.
76. Laufer I, Lis E, Pisinski L, Akhurst T, Bilsky M. (2009) The accuracy of 18-FFDG positron emission tomography as confirmed by biopsy in the diagnosis of spine metastases in a cancer population. Neurosurgery. 64:107-14.
77. Metser U, et al. (2004) Malignant involvement of the spine: assessment by 18F-FDG PET/CT. J. Nucl. Med. 45:279-84.
78. Langsteger W, Heinisch M, Fogelman I. (2006) The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin. Nucl. Med. 36:73-92.
79. Beheshti M, et al. (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur. J. Nucl. Med. Mol. Imaging. 35:1766-74.
80. Ambrosini V, et al. (2010). (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging. 37:722-7.
81. Seemann MD. (2007) Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18F-TOCA PET, triple-phase CT, and PET/CT. Technol. Cancer Res. Treat. 6:213-20.
82. Becherer A, et al. (2004) Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J. Nucl. Med. 45:1161-7.
83. Rosen RS, Fayad L, Wahl RL. (2006) Increased 18F-FDG uptake in degenerative disease of the spine: characterization with 18F-FDG PET/CT. J. Nuc. Med. 47:1274-80.
84. Harmoka T, et al. (2004) Bone imaging in metastatic breast cancer. J. Clin. Oncol. 22:2942-53.
85. Hanrahan CJ, Christensen CR, Crim JR. (2010) Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. Radiographics. 30:127-42.
86. Breyer RJ 3rd, Mulligan ME, Smith SE, Line BR, Badros AZ. (2006) Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol. 35:632-40.
87. Zamagni E, et al. (2007) A prospective comparison of 18Ffluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging, and whole- body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 92:50-5.
88. Shin D-S, et al. (2008) Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography. Skeletal Radiol. 37:415-21.
89. Schmitz A, et al. (2002) DG-PET Findings of vertebral compression fractures in osteoporosis: preliminary results. Osteoporos. Int. 13:755-61.
90. Shon IH, Fogelman I. (2003) F-18 FDG positron emission tomography and benign fractures. Clin. Nucl. Med. 28:171-5.
91. Kato K, Aoki J, Endo K. (2003) Utility of FDGPET in differential diagnosis of benign and malignant fractures in acute to subacute phase. Ann. Nucl. Med. 17:41-6.
92. Katzel JA, Heiba SI. (2005) PET/CT F-18 FDG scan accurately identifies osteoporotic fractures in a patient with known metastatic colorectal cancer. Clin. Nucl. Med. 30:651-4.
93. Tsuchida T, Kosaka N, Sugimoto K, Itoh H. (2006) Sacral insufficiency fracture detected by FDG-PET/CT: report of 2 cases. Ann. Nucl. Med. 20:445-8.
94. Aoki J, et al. (2001) FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 219:774-7.
95. Zhuang H, et al. (2003) Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur. J. Nucl. Med. Mol. Imaging. 30:1096-103.
96. Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS. (2007) Accuracy of fluorodeoxyglucose-positron emission tomography for diagnosis of single bone metastasis: comparison with bone scintigraphy. J. Comput. Assist. Tomogr. 31:812-9.
97. Parulekar WR, Eisenhauer EA. (2002) Novel endpoints and design of early clinical trials. Ann. Oncol. 13:139-43.
98. Korn EL, et al. (2001) Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol. 19:265-72.
99. Hanson MW, Hoffman JM, Glantz MJ. (1990) FDG-PET in the early postoperative evaluation of patients with brain tumor. J. Nucl. Med. 31:799.
100. Kim EE, et al. (1992) Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics. 12:269-79.
101. Haberkorn U, et al. (1993) Fluorodeoxyglucose imaging in advanced head and neck cancer after chemotherapy. J. Nucl. Med. 34:12-7.
102. DiChiro G, et al. (1988) Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR. Am. J. Radiol. 150:189-97.
103. Schaller B, et al. (2003) Hemodynamic and metabolic effects of decompressive hemicraniectomy in normal brain. An experimental PETstudy in cats. Brain Res. 982:31-7.
104. De Witte O, Hildebrand J, Luxen A, Goldman S. (1994) Acute effect of camastine on glucose metabolism in brain and glioblastoma. Cancer. 74:2836-42.
105. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int. J. Cancer. (Radiat. Oncol. Investig.) 96:191-7.
106. Hölzer T, Herholz K, Jseke HJ, Heiss WD. (1998) FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J. Comput. Assist. Tomogr. 17:681-7.
107. Meltzer C, Townsend DW, Kottapally S, Jadali F. (1998) FDG Imaging of spinal cord primitive neuroectodermal tumor. J. Nucl. Med. 39:1207-9.